CLX

Business profile & competitive position

The Clorox Company operates in the Consumer Defensive sector within the Household & Personal Products industry. Its business centers on branded cleaning, household, and personal-care products sold primarily through mass retailers, grocery chains, and e-commerce channels. As a defensive staples name, revenue is usually tied to recurring consumer purchases rather than discretionary cycles, which is reflected in the stock’s low beta of 0.53—meaning shareholders have historically experienced roughly half the market’s volatility.

Where the competitive-position read becomes complicated is the return-on-equity figure. CLX posts a net margin of 8.7%, which is a positive, mid-single-digit profitability profile typical of a large packaged-goods company. However, ROE stands at negative 1,893.5%. ROE is net income divided by shareholders’ equity, so a reading that extreme and negative usually signals that shareholders’ equity is itself negative or has been severely impaired through accumulated deficits, heavy buybacks, or balance-sheet restructuring. In other words, the denominator—not necessarily the earnings power—drives the distortion. That makes the 8.7% net margin the cleaner profitability lens, while the ROE figure warns that book value is not a reliable anchor for this equity.

Financial posture

Clorox currently carries a market capitalization of $12.9 billion and trades at a P/E ratio of 22.2 based on the current snapshot price of $106.9. That multiple sits at a premium to many broader market averages and reflects the stability premium investors often assign to defensive consumer names, even when growth is measured. The valuation becomes more interesting when set against the profitability mix: a positive 8.7% net margin supports earnings, while the negative ROE underlines that the capital structure has limited traditional equity cushion.

The 0.53 beta reinforces the low-risk, low-correlation profile, but it also means the stock may lag in strong rallies and may not fully participate in cyclical upswings. Technical positioning shows the stock has run above its 50-day exponential moving average of $98.26, with the RSI at 67.0—just below the commonly cited 70 overbought threshold. That combination suggests the shares have recently outperformed their short-term trend but are not yet flashing an extreme condition. The next earnings event, scheduled for November 3, 2026 after the close, carries a consensus EPS estimate of $1.07.

Macro & geopolitical exposure

As a Household & Personal Products company, Clorox is exposed to the macro forces that shape the consumer staples supply chain. Input-cost inflation is the most direct pressure: raw materials such as chemicals, resins, pulp-based packaging, and agricultural-derived ingredients all feed into household cleaning and personal-care products. Transportation, warehousing, and labor costs are also material, which is why management commentary on inflation consistently draws attention.

Regulatory risk is another industry-wide factor. Cleaning and personal-care products face ongoing scrutiny over ingredient safety, labeling, environmental claims, and chemical disclosure rules across multiple jurisdictions. Tariffs and trade policy can affect both imported raw materials and finished goods, while currency translation creates additional variance for any international revenue. Demand itself tends to be stable in recessions, but volume can be pressured by consumers trading down to private-label alternatives during prolonged inflation. In short, the sector offers defensive revenues, but margin stability depends heavily on cost management and pricing power.

Recent developments

Clorox’s most recent catalyst came from its fiscal fourth-quarter report, which dominated the August 2026 news flow. On August 4, 2026, Zacks highlighted that “Clorox Q4 Earnings & Sales Top Estimates as GOJO Supports Sales,” pointing to the Purell-parent acquisition as a contributor to the top-line outperformance. The same day, a separate Zacks headline noted that the “CLX Q4 Earnings Call Flags Inflation as Share Recovery Builds,” signaling that while results were better than expected, management remained focused on cost pressures. Also on August 4, 2026, Benzinga reported that “These Analysts Boost Their Forecasts On Clorox Following Better-Than-Expected Q4 Results,” suggesting at least some sell-side models were revised upward after the print.

Two days later, on August 6, 2026, Zacks published “NWL vs. CLX: Which Stock Is the Better Value Option?,” framing Clorox in a direct value comparison with Newell Brands. Taken together, the early-August cluster paints a picture of a company that beat expectations, received some estimate upgrades, but still faces valuation questions and inflation-related execution risk heading into the next fiscal year.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Clorox has beaten consensus earnings estimates six times, for a 75% beat rate, with an average earnings surprise of 9.4%. The average five-day drift following these reports has been 1.48%, classified as an upward drift. That said, the actual quarterly reactions have been inconsistent, and headline beats have not always translated into immediate price gains.

The most recent quarter, reported August 3, 2026, is the clearest example of that asymmetry. CLX delivered actual EPS of $1.66 against a $1.64 estimate, just a 1.2% positive surprise, yet the stock surged 6.52% the next day and 8.84% over the following five sessions. By contrast, the April 30, 2026 quarter was a larger 5.8% beat at $1.64 versus $1.55, but the stock tumbled 9.67% the next day and finished the five-day window down 4.49%. The February 3, 2026 quarter was a 2.8% miss, yet the stock rose 2.43% the next day and 5.63% over five days. Finally, the November 3, 2025 quarter was a 3.9% beat, producing a modest 1.17% next-day gain but a negative 4.08% five-day drift. This pattern shows that CLX’s post-earnings price action does not always move in lockstep with the size or direction of the EPS surprise, which is important context for anyone tracking the unofficial consensus around the November 3, 2026 report.

For investors who want more than the headline numbers, the full institutional verdict—covering analyst rating distributions, estimate revision trends, and historical surprises—can provide a deeper dive into how the market is positioning around Clorox ahead of the November report.